MACROECONOMIC AND INDUSTRY OVERVIEW
Global Economy
The global economy demonstrated continued resilience in 202526, navigating a complex environment of moderating inflation, geopolitical tensions, and trade disruptions. According to the IMF World Economic Outlook, global growth is projected to slow to 3.1% in 2026 and recover modestly to 3.2% in 2027, well below pre-pandemic averages, as the outbreak of war in the Middle East at the end of February 2026 has emerged as the most significant new disruption to the global economic outlook. According to the IMF World Economic Outlook (April 2026), global headline inflation is projected to rise to 4.4% in 2026, driven primarily by rising energy costs stemming from the outbreak of war in the Middle East, before resuming its decline to 3.7% in 2027. The IMF notes that absent the conflict, global growth would have been revised upward, underscoring that the current inflationary and growth headwinds are largely conflict-induced rather than structural, with downside risks continuing to dominate the global outlook. Global trade is expected to weaken in the near term due to geopolitical tensions, rising trade barriers, and ongoing supply chain disruptions. Trade fragmentation and tariff increases are identified as key risks that could further dampen economic activity and reduce long-term output.
For the healthcare sector, the 2026 macroeconomic environment presents a more challenging cost landscape than the previous year. Rising commodity prices,elevatedinflation,andtighterfinancialconditions driven by the Middle East conflict are increasing energy costs, medical consumable expenses, pharmaceutical import prices, and capital equipment procurement costs across hospital networks in emerging markets. Emerging market economies face particular sensitivity to energy cost fluctuations and currency volatility during periods of geopolitical uncertainty. Unihealths revenues are substantially denominated in multiple African currencies, including the Ugandan Shilling, Tanzanian Shilling and Nigerian Naira. While currency movements remain an important consideration for the translation of overseas operations into the Companys consolidated INR financial statements, the overall impact during FY26 has been largely mitigated due to broad-based currency depreciation across emerging markets.
During the year, both the Indian Rupee and the African operating currencies depreciated against the US Dollar; however, the depreciation of the Indian Rupee was higher compared with the relative movement in the major African currencies. Accordingly, the translation impact arising from the conversion of African revenues into INR has not resulted in a significant adverse impact on the Companys consolidated financial performance. The Companys reported INR revenues therefore continue to primarily reflect the underlying operational performance of its African businesses rather than being materially impacted by foreign currency translation movements.
Indian Economic Overview
According to RBI Annual Report 2025-26, India reaffirmed its position as the worlds fastest-growing major economy in FY26, recording GDP growth of 7.6%, supported by resilient domestic consumption, sustained capital investment, proactive policy initiatives, and robust macroeconomic fundamentals. Despite heightened geopolitical tensions, evolving global trade dynamics, and persistent external uncertainties, the economy demonstrated remarkable resilience, underpinned by strong domestic demand and a stable policy environment. The countrys strong growth trajectory, rising disposable incomes, expanding urbanisation, and continued public and private investments are creating a robust foundation for the healthcare sector. Increasing healthcare awareness, greater insurance penetration, and a growing emphasis on quality medical services are driving demand while encouraging capacity expansion and technological advancement across the industry. Reflecting this strategic focus, the Union Budget 202627 introduced several flagship initiatives aimed at strengthening Indias healthcare and life sciences ecosystem. According to the RBI Annual Report 2025 26, among them, the Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology, and Innovation) scheme, with an outlay of Rs. 10,000 Cr over five years, seeks to enhance the countrys capabilities in the production of biologics and biosimilars. The initiative is expected to foster research and innovation, strengthen domestic manufacturing, reduce import dependence, and position India as a competitive global hub for advanced biopharmaceuticals.
Indian Healthcare Industry
Indias healthcare sector continues to be one of the countrys largest and fastest-growing industries, supported by rising healthcare awareness, increasing life expectancy, expanding health insurance penetration, technological advancement, and growing investments in healthcare infrastructure. The sector encompasses hospitals, diagnostics, pharmaceuticals, medical devices, telemedicine, health insurance, clinical research and medical tourism, positioning India as an emerging global healthcare hub.
The Indian healthcare industry reflects sustained demand for quality healthcare services and increased public and private sector participation. The hospital segment remains a key contributor to Indias healthcare ecosystem. According to the India Brand Equity Foundation (IBEF), the Indian hospital market was valued at approximately US$98.98 billion in 2023 and is projected to reach approximately US$193.59 billion by 2032, growing at a CAGR of around 8.0% during 20242032. The growth outlook is supported by increasing healthcare expenditure, expansion of hospital capacity, rising demand for tertiary and specialised care, improving healthcare accessibility, and increased investments by private healthcare providers.
Healthcare expenditure in India remains on an upward trajectory, with total healthcare spending expected to increase from approximately 3.3% of GDP in 2022 to around 5% of GDP by 2030, reflecting the sectors growing strategic importance in the Indian economy. The growth outlook is further supported by increasing insurance coverage, government healthcare initiatives, digital health adoption, medical tourism, and continued investments by private healthcare providers to bridge infrastructure gaps.
Going forward, Indias healthcare sector is expected to witness sustained expansion driven by demographic changes, rising prevalence of lifestyle-related diseases, increasing demand for tertiary and quaternary care, improved healthcare accessibility, and continued investments in hospital infrastructure and technology. The sector is therefore expected to remain a key growth driver within Indias services economy over the medium to long term.
Several structural shifts are reshaping the landscape: Insurance Penetration: Health insurance now contributes approximately one-third of overall general insurance premiums in India, reflecting rising awareness and adoption. Government schemes like Ayushman Bharat have significantly expanded the insured population base, creating a new and growing paying-patient segment for hospitals.
Tier 2 and Tier 3 Opportunity: Despite impressive aggregate growth, significant quality and capacity gaps persist in Tier 2 and Tier 3 cities. Rising incomes and health awareness in these markets, combined with limited availability of quality tertiary care, create a compelling long-term demand opportunity for hospital operators willing to invest in these geographies, a space where Unihealth has deliberately positioned itself through its Maharashtra "Golden Triangle" strategy for the first phase of its growth in India.
Medical Tourism: According to Press Information Bureau of India (PIB India), in 2025, India has attracted over 507,244 foreign medical tourists, which is 5.5% of the total FTAs (Foreign Tourist Arrivals) in recent years, establishing itself as one of the top global destinations for affordable, high-quality treatment. According to the India Brand Equity Foundation (IBEF), the Indian medical tourism market is projected to grow to US$16.21 billion by 2030, at a CAGR of 13.23%, creating strong demand for internationally connected hospital networks like Unihealths.
Digital Health: The telemedicine market is expected to touch US$5 billion, with the digital health market projected to grow at high double-digit rates. AI-driven diagnostics, electronic health records, and tele-consultation are transitioning from pilots to mainstream adoption across Indian hospitals.
Pharmaceutical Strength: According to the India Brand Equity Foundation (IBEF), Indias pharmaceutical sector remains a cornerstone of global healthcare supply, with significant export growth projected to reach US$350 billion by FY47, a tailwind that directly supports Unihealths pharmaceutical distribution vertical.
African Healthcare Industry
Africas healthcare landscape is at an inflection point.
According to Statista & Africa Europe Foundation, despite holding around 18% of the global population, Africa accounts for less than 1% of global health expenditure and just 3% of the worlds healthcare workforce, while bearing 24% of the global disease burden. This structural imbalance creates one of the most compelling long-term investment theses in global healthcare.
Key structural drivers include a youthful and expanding population, rapidly rising incomes, and growing demand for quality tertiary care. According to World Health Organization (WHO) African Region, non-communicable diseases like diabetes, hypertension, cardiovascular disease, now account for 37% of deaths in Sub-Saharan Africa, creating sustained demand for the kind of specialty and tertiary-care services that Unihealths UMC Hospitals network delivers. Simultaneously, countries like Kenya, Uganda, and Tanzania are expanding national health insurance coverage, broadening the paying-patient base.
Digital Health Trends
According to Capgemini, the healthcare sector is undergoing a profound transformation, driven by the rapid adoption of digital technologies and artificial intelligence across the global healthcare ecosystem. Providers are increasingly leveraging AI-enabled diagnostics, predictive analytics, electronic health records, and intelligent automation to enhance clinical decision-making, streamline administrative processes, and deliver more personalised patient care. Generative AI is also reshaping hospital operations by reducing documentationburdens,improvingworkflowefficiency, and enabling clinicians to devote greater attention to patient outcomes. As healthcare delivery evolves towards a more data-driven, preventive, and patient-centric model, investments in digital infrastructure and technology-enabled care solutions are becoming critical enablers of long-term operational excellence and sustainable growth.
From Unihealths perspective, digital transformation remains a key enabler in strengthening healthcare delivery, improving operational efficiency, and enhancing patient experience across its healthcare network. The Company continues to recognise the importance of technology-led healthcare solutions in supporting clinical excellence, data-driven decision-making, and seamless delivery of healthcare services across its operating geographies. The adoption of digital platforms, integrated hospital information systems, electronic medical records, analytics-driven insights, and technology-enabled operational processes is expected to further enhance care coordination, improve resource utilisation, and support scalable growth.
As Unihealth continues to expand its presence across emerging healthcare markets, the Company remains focused on leveraging innovation and digital capabilities to build efficient, accessible, and patient-centric healthcare ecosystems. By combining clinical expertise with technology-driven solutions, Unihealth aims to strengthen healthcare outcomes while creating sustainable long-term value for patients, stakeholders, and communities it serves.
COMPANY OVERVIEW AND STRATEGIC ROADMAP
From Medical Travel Facilitator to Integrated Healthcare Platform Unihealth Hospitals Limited, listed on NSE Emerge in September 2023, has undergone a remarkable strategic transformation since its founding in Mumbai in 2010. What began as a pioneering Medical Value Travel facilitation company has evolved, over sixteen years, into an integrated multi-country tertiary-care platform operating under the flagship brand UMC Hospitals.
This evolution reflects a disciplined, phase-wise expansion: from healthcare consultancy and medical travel facilitation (20102016), to commissioning and operating tertiary-care hospitals in Uganda and Tanzania (20162022), to consolidating African operations while simultaneously launching an India hospital-delivery platform (20232026). The renaming of the Company from Unihealth Consultancy Limited to Unihealth Hospitals Limited in October 2024 formalises this identity shift and signals to all stakeholders that hospital operations are, and will remain, the core of the business.
The Integrated Ecosystem
Unihealth operates four synergistic verticals that reinforce one another: Hospitals & Medical Centres anchor the platform, delivering scale and clinical credibility. Medical
Value Travel creates cross-border patient flows between Africa and India, enhancing occupancy and revenue per occupied bed at Indian facilities. Healthcare Consultancy builds market relationships and recurring fee income, with Design-Build-Operate mandates creating long-term O&M contract pipelines. Pharmaceutical & Medical Consumables Distribution reduces input costs for captive hospital use while generating high-margin third-party revenue.
Together, these verticals create a self-reinforcing ecosystem where each element strengthens the others, a model that differentiates Unihealth from single-vertical hospital operators and provides resilience across market cycles.
The Asset-Light Approach
Unihealth has consciously adopted, for its first phase of expansion in India, an asset-light model, focused on leased hospital properties to ensure capital-efficient scaling. This approach dramatically reduces upfront capital requirements, where a 50-bed greenfield facility can be commissioned for Rs. 1517 Cr in capex and a 175-bed can be commissioned for Rs. 2830 Cr in capex. This helps the Company preserve its balance sheet flexibility for clinical equipment, technology, and working capital investment as it intends to enter a phase of rapid expansion in the coming few years. Dual-Geography Rationale The dual India-Africa strategy is deliberate and mutually reinforcing, not merely opportunistic. Africa delivers high-margin, mature revenue from facilities that have been operational for nearly a decade, generating institutional expertise, cash flows, and clinical protocols that now inform the India build-out. India, in turn, offers the scalability that Africa alone cannot provide - a large, growing, insurance-backed domestic market where Unihealth can build a multi-thousand bed platform over the long term.
India also serves as a strategic manpower development base. The India hospitals allow Unihealth to recruit, train, and culturally assimilate clinical and administrative talent like nursing staff, technicians, hospital administrators, who can subsequently be deployed in African facilities as the network expands. This human capital pipeline is a competitive moat that few peers can replicate.
BUSINESS VERTICAL REVIEW
Hospitals & Medical Centres: The Core of Unihealth Hospitals and Medical Centres remain the dominant revenue contributor, accounting for approximately 82% of consolidated revenues in FY25 and an even higher proportion in FY26 given the addition of new facilities. The network spans three countries across two continents:
UMC Victoria Hospital, Kampala (Uganda): The flagship 120-bed tertiary-care facility, in operation since 2017, has evolved into one of Ugandas premier private hospitals. In FY26, the facility invested significantly in infrastructure upgrades like patient room renovations, operating theatre upgrades, as part of a comprehensive refresh ahead of its next growth phase. Specialty additions including IVF (first successful IVF twin birth achieved this year), neurosurgery, advanced orthopaedic and spine care, and ophthalmology (cataract surgery programme being launched) have meaningfully enhanced the case mix and ARPOB trajectory. The facility is now debt-free, and is generating strong free cash flows.
UMC Hospital, Navi Mumbai (India): Commissioned as a soft launch in October 2025, the 50-bed multi-specialty tertiary-care facility received its final critical licenses, including certain key operating permissions in February 2026, enabling full-spectrum critical care services. In the first 22.5 months of full operations (mid-February to March 31, 2026), the facility generated approximately Rs. 3 Cr in revenue with an ARPOB of Rs. 32,00032,500, exceeding the initial forecast of Rs. 27,500. The hospital has 130+ consultants on its panel across all key specialties, ensuring round-the-clock multi-specialty, super-specialty care for its patients. Key procedures successfully performed at the facility within the first few months of its commissioning include complex cardiac bypass surgeries, craniotomies, and most recently its first Robotic Total Knee Replacement Surgery, performed on June 2, 2026, marking a landmark clinical milestone for the facility and for advanced orthopaedic care in the region.
UMC Hospitals, Nashik (India): The 200-bed flagship North Maharashtra facility of the Company has received its official Hospital Registration as of June 10, 2026, marking the completion of the critical regulatory milestone. Final commissioning activities, staff onboarding, clinical workflow validation, equipment calibration, mock drills, and operational simulations, are currently underway. Patient services are expected to commence in the coming weeks, with full operational launch targeted for the end of July 2026. The facility will offer an extensive range of specialties including Cardiology, Orthopaedics & Spine Surgery, Neurology, Neurosurgery, Nephrology, Gastroenterology, Pulmonology, Urology, Oncology, Mother & Child Care, and comprehensive Pathology and Radiology services. The infrastructure includes state-of-the-art ICU beds, a Cardiac Catheterisation Laboratory (Cath Lab), four Modular Operation Theatres including a dedicated Robotic Surgery OT, and a full range of inpatient accommodation options.
UMC Hospital, Entebbe (Uganda): As part of its continued efforts to strengthen its healthcare presence in Uganda and consolidate its position as a leading healthcare provider in the region, the Group successfully acquired and commissioned this 30-bed healthcare facility during Q4 FY26. This strategic addition represents an important milestone in the Groups East African expansion journey, further enhancing its ability to deliver accessible and quality healthcare services closer to its patients and corporate partners.
The facility is designed to provide comprehensive healthcare support, featuring multiple consultation rooms, diagnostic services, an in-house pharmacy, inpatient facilities, and standard operating theatres. The addition of this facility expands the Groups service capabilities and complements its existing healthcare network by enabling more efficient patient access, improved care coordination, and enhanced service delivery.
The acquisition further strengthens the Groups engagement with key corporate clients and communities in Uganda by providing a broader platform for delivering integrated healthcare solutions. This expansion reflects Unihealths continued commitment towards building scalable healthcare infrastructure, enhancing regional accessibility, and creating sustainable value across its operating markets.
Healthcare Consultancy
Unihealths consultancy vertical provides end-to-end healthcare project advisory under a Design-Build-Operate model, spanning feasibility studies, architectural planning, medical procurement, quality management, and operations management. The vertical currently manages mandates for approximately 1,300 beds across multiple projects in India, Africa, and the Middle East.
The flagship mandate is the PHRC Health City, Pune a 750-bed integrated healthcare and education campus comprising a 150-bed private wing and a 600-bed teaching hospital with a MBBS degree college. The groundbreaking ceremony was conducted by Union Home Minister Shri Amit Shah, with construction excavation commencing now. The project is expected to be commissioned over the next 5 years. Consultancy margins run at approximately 60-65%, making this an exceptionally high-margin vertical that supplements hospital revenues and provides market credibility.
Pharmaceutical & Medical Consumables Distribution Unihealth operates as an authorised distributor of medical consumables and pharmaceutical products, exporting from India to multiple African countries. Distribution partnerships include leading Indian companies Reliance Life Sciences, Levram Lifesciences, Fixderma India, Unisur Lifecare, and Hemant Surgical providing a reliable and expanding product portfolio.
This vertical serves a dual strategic purpose: it reduces procurement costs for captive hospital consumption within the UMC network, while simultaneously generating third-party distribution revenues at margins of approximately 2535%. The vertical is being expanded through new distribution rights agreements, with a focus on diversifying the product mix to cover both pharmaceutical and surgical consumable categories.
Medical Value Travel (MVT)
The MVT vertical facilitates end-to-end medical travel for international patients seeking advanced treatment in India, offering pre-travel clinical assessment, visa assistance, in-India concierge services, and post-treatment follow-up. Unihealths African hospital network serves as a natural feeder system for complex procedures that require technology or specialist expertise not yet available in East Africa.
In FY26, the MVT vertical demonstrated strong momentum: the Navi Mumbai hospital has already received international patients from Uganda and Tanzania, with the first international patient admitted within weeks of commissioning. As of the earnings call on June 3, 2026, there were over 250 live patient inquiries from Africa including Nigeria, Uganda, Tanzania, and Kenya at various stages of the referral pipeline. The Company is also actively targeting patient flows from Kenya and Nigeria, with Middle Eastern markets (Oman, Iraq) earmarked for activation once regional geopolitical conditions stabilise
| Particulars | FY24 | FY25 | FY26 |
| Medical Centres & Hospitals | Rs. 74.5 Cr | Rs. 93.0 Cr | Rs. 117.8 Cr |
| Export & Distribution of Pharmaceuticals & Medical Consumables | Rs. 1.9 Cr | Rs. 4.3 Cr | Rs. 9.3 Cr |
| Medical Value Travel | - | - | - |
| Consultancy Services | Rs. 7.6 Cr | Rs. 1.7 Cr | Rs. 5.0 Cr |
Revenue from Operation |
Rs. 84.0 Cr | Rs. 99.1 Cr | Rs. 132.0 Cr |
OPERATIONAL AND CLINICAL PERFORMANCE
Bed Capacity Expansion
FY26 was a transformational year for Unihealths physical infrastructure. The Company doubled its commissioned bed capacity from approximately 200 beds at the start of FY26 to approximately 400 beds by year-end, a milestone achieved through the commissioning of Navi Mumbai, the acquisition of UMC Entebbe, and the near-completion of Nashik. The trajectory through FY27 and beyond is clearly charted:
| Period | Commissioned Beds (Approx.) |
| Start FY26 | 200 |
| End FY26 | 400 |
| End FY27 (Target) | 600 |
| CY2028 (Target) | 1,000 |
Facility Commissioning
Navi Mumbai: Soft-launched October 2025; full critical care services operational from mid-February 2026 upon receipt of necessary statutory licenses. The facility has completed its initial ramp-up period and is on track to achieve operational breakeven by Q2 FY27 (September 30, 2026).
Nashik: Hospital Registration received June 10, 2026. Final commissioning activities underway. Patient services are expected to commence by the end of July 2026. Operational breakeven targeted within 15-18 months of commissioning, with full CT and MRI capabilities operational by August 2026.
UMC Entebbe (Uganda): Acquired and commissioned during FY26, adding 30 beds to the East African network.
Tanzania- Mwanza (20-bed Specialised Hospital):
Infrastructure is fully ready. The first site visit by regulatory authorities has been completed, and the second site visit, the final step before license issuance is awaited. Licenses expected within 4-6 weeks of the earnings call (June 2026), with services commissioning to follow promptly.
Tanzania- Dar-es-Salaam (100-bed Tertiary Hospital):
Commercial negotiations and draft agreements have been exchanged. Legal and statutory approvals are the final pending step, expected to conclude within 23 months. Being an existing operational facility, revenue contribution is expected from the date of takeover. Clinical Excellence Milestones FY26 saw the achievement of several landmark clinical milestones that reflect the growing depth of Unihealths specialist capabilities:
First IVF Twin Birth at UMC Victoria Hospital, Kampala:
A landmark achievement for reproductive medicine in Uganda, demonstrating the facilitys growing capabilities in advanced specialty care and its commitment to delivering superior patient outcomes in East Africa.
FirstRoboticTotalKneeReplacementatUMCHospitals, Navi Mumbai (June 2, 2026): A defining milestone for orthopaedic care in the region. The procedure, performed using state-of-the-art robotic technology, delivers greater surgical precision, enhanced implant alignment, reduced tissue trauma, and improved post-operative outcomes. Patients can expect faster recovery, reduced post-operative pain, shorter hospital stays, and enhanced long-term mobility.
First IVUS-Guided Coronary Intervention at UMC Hospitals,NaviMumbai(June14,2026):Asteptowards redefining cardiac care at UMC Hospitals, Intravascular Ultrasound (IVUS) is a highly sophisticated imaging technology that uses a miniature ultrasound probe mounted on the tip of a coronary catheter and provides a two-dimensional silhouette of the blood vessels using contrast dye, enabling physicians to visualize the artery from within, offering detailed cross-sectional images of the vessel wall, plaque composition, calcium burden, and the exact dimensions of the artery. The successful execution of this procedure reflects the continued focus of UMC Hospitals on investing in advanced medical technologies and evidence-based treatment protocols.
Cardiac and Neurosurgical Excellence: UMC Hospitals Navi Mumbai has successfully performed cardiac bypass surgeries and craniotomies, establishing its credentials as a genuine tertiary-care facility within months of commissioning.
REGIONAL PERFORMANCE: CONNECTED GEOGRAPHIES
Africa Uganda: The Mature Engine
Uganda remains the primary revenue driver for the Group, contributing Rs. 115.3 Cr (approximately 79%) of consolidated total revenues of Rs. 145.8 Cr in FY26. UMC Victoria Hospital, Kampala, in its ninth year of operations, has established itself as one of Ugandas leading private tertiary-care hospitals and is now a mature, cash-generating asset.
H2 FY26 revenues from Uganda showed a temporary dip of approximately 17% relative to H1, driven by two seasonality factors: the DecemberJanuary Christmas break (during which elective surgeries decline sharply as affluent patients and local citizens travel away from Kampala) and Ugandas five-year general elections held on January 15, 2026 (which effectively extended the lean period through late January). These factors are non-recurring seasonal and political events, and Uganda operations have resumed their growth trajectory from February 2026 onwards.
The facility is investing in specialty deepening: IVF (first twin birth achieved), neurosurgical microscope, advanced cardiology setup, and ophthalmology (cataract surgery programme imminent) are all being added to the clinical mix, driving ARPOB expansion. Africa Tanzania: The Emerging Frontier Tanzania represents Unihealths most active expansion frontier in Africa. Two projects are in advanced stages: The 20-bed specialised hospital in Mwanza is construction-complete and awaiting its second regulatory site visit, after which licenses are expected to be issued. A one-quarter delay was caused by Tanzanias general elections and the resulting administrative backlog. Commissioning of services is expected shortly after license receipt.
The 100-bed tertiary care hospital in Dar-es-Salaam, following conclusion of the commercial negotiations, is awaiting clearance from the legal and tax consultants for the draft agreements exchanged between parties. Being an existing operational facility with a baseline revenue, this acquisition will result in an immediate revenue addition from takeover. Significant expansion of the facility is planned in the 24 quarters post-acquisition.
Africa Nigeria: Strategic Pivot
Following the exit from UMC Zhahir Hospital, Kano, a decision made as part of the Companys strategic portfolio review, Nigeria has been repositioned as a Medical Value Travel source market rather than a hospital operations geography. This strategic pivot reflects a rational assessment: the operational and regulatory complexity of Nigerian hospital operations relative to returns, versus the strong demand for Indian medical travel among Nigerias sizeable and relatively affluent healthcare-seeking population. India: Building the Maharashtras "Golden Triangle" India is Unihealths highest-growth geography and this trajectory will accelerate sharply as Nashik reaches full operational capacity in FY27.
The India strategy is anchored in Maharashtras "Golden Triangle" Mumbai, Nashik, and Pune: Navi Mumbai (50 beds): Operational since October 2025; full critical care services from February 2026. On track for operational breakeven by Q2 FY27. Nashik (200 beds): Hospital Registration received on June 10, 2026. Patient services commencing imminently. Nashik addresses a significant quality gap in North Maharashtra, where the population of approximately 2 million in Nashik city and the broader district has historically had to travel to Mumbai or Pune for tertiary-care services.
Pune (125 beds, Planned): A greenfield facility is being evaluated for a later phase of the Maharashtra rollout. The PHRC Health City (750 beds) represents a Phase 2 O&M opportunity.
Indias positioning as a medical value travel destination for African patients further enhances the economics of the India hospitals, creating a natural synergy between the Companys two operating geographies.
UAE and Mauritius: Supporting Geographies
UAE ( Rs. 4.4 Cr, FY26) contributes primarily through the Aryavarta FZE management consultancy services entity. Mauritius ( Rs. 0.3 Cr, FY26) serves as a holding and investment vehicle for African operations. Both geographies provide structural and operational support to the Groups primary operating markets.
HUMAN RESOURCE DEVELOPMENT
Unihealths most critical asset is its people. With a workforce of 500+ employees spread across India, Uganda, Tanzania, Nigeria, and the UAE, the Companys human capital strategy is built around three pillars: local employment and knowledge transfer in Africa, clinical talent development in India, and cross-border expertise exchange.
Workforce Composition and Local Employment Over 95% of the workforce in African operations is locally employed, a deliberate policy that fosters community trust, drives knowledge transfer, and aligns with the Companys ESG commitments. This locally-anchored workforce, supplemented by senior clinical and management leadership, gives UMC Hospitals a level of community integration and patient trust that externally-staffed competitors cannot replicate. Capacity Building and Training Unihealth invests in specialised training across its hospital network, covering intensive care protocols, diagnostic imaging, surgical support, and continuous medical education (CME) programs developed in partnership with regional and international medical institutions. In FY26, the introduction of structured leadership and management training programs has begun developing the next generation of healthcare leaders within the organisation.
Doctor Retention Strategy: A Distinctive Approach Attracting and retaining quality clinical talent is the most critical operational challenge for a hospital group in Indias competitive market. Unihealth has developed a differentiated retention model built on three elements:
Infrastructure Parity: Navi Mumbai offers clinical infrastructure like modular OTs, Cath Lab, ICU, robotic surgery comparable to any large corporate hospital, ensuring that senior consultants have the tools they need to perform complex procedures.
Agility and Flexibility: Unlike large corporate chains, Unihealth offers consultants genuine flexibility in case selection, pricing, and scheduling, attributes that a growing cohort of mid-career specialists (aged 3550) actively seek.
Daily-to-Weekly Payment Settlement: Consultant dues are settled within days of patient discharge, directly crediting the doctors account. This stands in marked contrast to the monthly settlement cycles of large corporate hospitals and has proven highly effective in building loyalty and comfort, particularly with consultants new to the Unihealth network. Navi Mumbai now has 130+ consultants on panel, testament to the success of this approach.
Cross-Border Talent Development
Indias hospitals serve as a talent incubation centre for the broader Unihealth network. Staff recruited and trained in India absorb the Unihealth clinical culture and operating protocols, and can be deployed in African facilities as the network expands, ensuring cultural alignment, operational consistency, and reduced dependence on external hires in challenging overseas markets.
Leadership Development
Senior management continues to engage in advanced leadership programs at ISB, IIMs, and other premier institutions. In Africa, Regional Leadership Hubs are being developed to groom middle managers and reduce reliance on expatriate leadership over time a key element of sustainable, locally-anchored growth.
FINANCIAL PERFORMANCE REVIEW
FY26 Consolidated Results
FY26 was a landmark year for Unihealths financial performance, delivering simultaneous acceleration in revenue growth, margin expansion, and profitability a combination that validates the operating leverage inherent in the platform.
| Metric | FY25 | FY26 | YoY Change |
| Total Income | Rs. 101.8 Cr | Rs. 137.0 Cr | ? 34.6% |
| EBITDA | Rs. 39.5 Cr | Rs. 58.8 Cr | ? 48.9% |
| EBITDA Margin | 38.8% | 42.9% | ?410 bps |
| PBT | Rs. 30.4 Cr | Rs. 46.3 Cr | ? 52.3% |
Net Profit (attributable) |
Rs. 14.1 Cr | Rs. 25.8 Cr | ? 82.9% |
| Diluted EPS ( Rs. ) | Rs. 9.17 | Rs. 16.52 | ? 80.2% |
Year Financial Trajectory
| Metric | FY24 | FY25 | FY26 |
| Total Income | Rs. 85.0 Cr | Rs. 101.8 Cr | Rs. 137.0 Cr |
| EBITDA | Rs. 31.4 Cr | Rs. 39.5 Cr | Rs. 58.8 Cr |
| EBITDA Margin | 36.9% | 38.8% | 42.9% |
| Net Profit Attrib. | Rs. 10.3 Cr | Rs. 14.1 Cr | Rs. 25.8 Cr |
| EPS ( Rs. ) | Rs. 6.67 | Rs. 9.17 | Rs. 16.52 |
Total Income grew 61.1%, from Rs. 85.0 Cr in FY24 to Rs. 137.0 Cr in FY26, driven by the maturity of Uganda operations and the initial contribution from India.
EBITDA increased 87.3%, from Rs. 31.4 Cr in FY24 to Rs. 58.8 Cr in FY26, reflecting strong operating leverage and the efficiency of the asset-light hospital model.
Net Profit attributable to shareholders rose 150.5%, from Rs. 10.3 Cr in FY24 to Rs. 25.8 Cr in FY26, supported by operational improvements and a stronger cost structure following debt repayment in Uganda.
EBITDA Margin expanded by 600 bps, from 36.9% in FY24 to 42.9% in FY26, driven by scale benefits, an improved service mix, and disciplined cost management.
FY25 Total Income nearly doubled to Rs. 101.8 Cr, driven by the consolidation of UMC Global Health and the expansion of Uganda operations. FY26 growth of 34.6% was led by organic expansion and the ramp-up of the India business.
Geographic Revenue Analysis
| Geography | FY25 | FY26 | Growth |
| Uganda | Rs. 87.0 Cr | Rs. 115.3 Cr | ?32.5% |
| India | Rs. 12.1 Cr | Rs. 25.0 Cr | ?106.6% |
| UAE | Rs. 0.4 Cr | Rs. 4.4 Cr | ?1000.0% |
| Nigeria | Rs. 6.6 Cr | Rs. 0.7 Cr | Strategic pivot |
| Tanzania | Rs. 0.6 Cr | Rs. 0.2 Cr | Pipeline stage |
| Mauritius | Rs. 0.1 Cr | Rs. 0.3 Cr | ?200.0% |
Total |
Rs. 106.8 Cr | Rs. 145.9 Cr | ?36.6% |
Uganda remained the key revenue driver, contributing Rs. 115.3 Cr, with 32.5% YoY growth driven by higher patient volumes and an improved procedure mix.
India emerged as the fastest-growing market, with revenue increasing 106.6% YoY to Rs. 25.0 Cr, supported by consultancy income and the initial contribution from the Navi Mumbai hospital.
Africa delivered a robust 3-year CAGR of ~75.3%, highlighting sustained demand across the region.
Nigerias revenue declined to Rs. 0.7 Cr following the strategic shift from hospital operations to a Medical Value Travel sourcing market.
Tanzania contributed Rs. 0.2 Cr in FY26, with significant revenue expected from new facilities commencing operations from FY27.
FY27 is expected to see a more balanced geographic revenue mix as the Nashik hospital scales up, reducing dependence on Uganda. Rs. Ratio Analysis
| Ratio | FY24 | FY25 | FY26 |
| Net Profit Margin (%) | 12.1% | 13.9% | 18.8% |
| Debt-to-Equity (x) | 0.22x | 0.12x | 0.11x |
| Interest Coverage | 4.43x | 10.65x | 20.79x |
| Ratio (x) | |||
| Current Ratio (x) | 4.56x | 3.78x | 5.34x |
Net Profit Margin improved to 18.8% in FY26 from
13.9% in FY25, driven by operating leverage, lower finance costs, and disciplined cost management.
Debt-to-Equity declined sharply from 0.22x in FY24 to 0.11x in FY26, reflecting strong deleveraging through operational cash generation while maintaining a conservative leverage profile.
Interest Coverage Ratio improved to 20.79x in FY26, reflecting a stronger earnings profile and enhanced debt-servicing capacity.
Current Ratio strengthened to 5.34x in FY26 from 3.78x in FY25, highlighting a strong liquidity position and sufficient working capital to support future growth.
DIGITAL TRANSFORMATION AND ESG
Healthcare IT and Digital Infrastructure
Unihealths digital health strategy is focused on improving clinical outcomes, reducing administrative friction, and extending its reach through technology. Tele-Medicine and Tele-Healthcare Centres are operational across the network, enabling remote consultation capabilities that are particularly impactful in Sub-Saharan Africa where specialist access is limited. The Company is investing in electronic health records, AI-driven diagnostic tools, and integrated hospital management systems as part of its broader commitment to globally benchmarked clinical protocols.
The integration of robotic surgery at Navi Mumbai demonstrated by the first Robotic Total Knee Replacement performed on June 2, 2026, reflects the Companys commitment to clinical technology adoption. As the India network scales, technology standardisationacrossfacilitieswillbeakeyoperational priority, enabling consistent quality delivery and data-driven management decision-making.
Environmental Stewardship
Unihealth is committed to reducing its environmental footprint across operations: Renewable Energy: The Company has invested in setting up a 65.5 kW rooftop solar power unit at its Navi Mumbai hospital facility, generating a total of 6212 units of power during Q4 of FY26, post the commissioning of the unit in January 2026. Investment in solar rooftop panels is planned across all existing and upcoming hospital facilities, with feasibility study completed for the hospital in Kampala, Uganda. This will reduce dependence on grid power a particularly impactful initiative in East Africa where power reliability and costs are significant operating variables.
Waste Management: The Company is targeting 100% recycling of paper, plastic, and non-medical organic waste. Domestic wet waste composting through compost pit installations is operational at a hospital facility in Uganda. Segregation, collection, and recycling initiatives for paper and recyclable waste are underway in Uganda and India.
Responsible Operations: The Companys asset-light, leasehold model minimises the environmental footprint of new hospital infrastructure relative to greenfield owned-property development.
Social Impact
Unihealths social impact is tangible and measurable, extending well beyond financial returns:
Community Healthcare: Regular Free Medical OPDs and outreach programs in India (Navi Mumbai) and Uganda bring quality healthcare to underserved communities. Free second-opinion services are provided to African patients to support informed healthcare decisions. Paediatric cardiac surgeries, in collaboration with like-minded non-profit organizations from Nigeria are provided to Nigerian children as part of the Companys community health commitment.
Local Employment: Over 95% of the 600+ workforce in African operations is locally recruited, supporting skill development, knowledge transfer, and community economic empowerment.
Inclusion: Collaboration with local support groups and foundations, and ongoing support for children with disabilities in Uganda, reflect the Companys commitment to inclusive community impact.
Governance
The Company voluntarily adopted Indian Accounting Standards (IND AS), aligned with IFRS, to enhance transparency and comparability of financial reporting. The Board maintains a well-constituted governance structure with a majority of independent directors on key committees. The Whistle Blower Policy (Vigil
Mechanism), Code of Internal Procedures for Insider Trading Regulation, and a formally documented Related Party Transaction Policy are all in place and publicly available. The Statutory Auditors report and Secretarial Audit Report for FY26 contain no qualifications, reservations, or adverse remarks, reflecting the Companys commitment to rigorous governance standards.
OPPORTUNITIES AND THREATS
Opportunities
Expansion in Underserved Healthcare Markets:
Growing demand for quality tertiary healthcare services in underserved and rapidly growing suburbs of Tier I cities and Tier II cities, coupled with increasing healthcare awareness and rising incomes, presents significant opportunities for capacity expansion and improved market penetration.
Increasing Health Insurance Coverage: The expansion of government-sponsored and private health insurance schemes is improving healthcare accessibility and affordability, broadening the addressable patient base and supporting higher utilisation of organised healthcare facilities.
Growing Healthcare Demand in East Africa: Structural gaps in healthcare infrastructure, limited availability of specialised services, and increasing investment in healthcare systems across East Africa continue to create long-term growth opportunities for established private healthcare providers.
Medical Value Travel: Indias cost competitiveness, skilled clinical workforce, and high-quality healthcare services are strengthening its position as a preferred destination for international patients, creating opportunities to leverage the Companys cross-border network.
Operational Leverage from Capacity Expansion:
As recently commissioned facilities mature and occupancy levels improve, the fixed-cost nature of hospital operations is expected to enhance operating leverage and support margin expansion.
Digital Healthcare and Technology Adoption:
Increasing adoption of telemedicine, artificial intelligence, and digital health platforms offers opportunities to enhance patient engagement, improve clinical outcomes, expand specialist access, and optimise operational efficiency.
Healthcare Management and Consultancy Services: The Companys growing expertise in hospital development and management services presents opportunities to establish long-term asset-light revenue streams through operations and management contracts.
Strategic Partnerships and Capital Deployment:
Rising investor interest in the healthcare sector provides opportunities for strategic collaborations, institutional partnerships, and capital infusion to support future expansion initiatives.
Integrated Pharmaceutical Distribution: The expansion of the hospital network provides opportunities to strengthen pharmaceutical procurement and distribution capabilities, creating operational synergies and improving supply chain efficiencies.
Policy Support and Healthcare Innovation:
Continued government focus on healthcare infrastructure, digital health initiatives, and domestic biopharmaceutical manufacturing is expected to strengthen the sectors long-term growth prospects and create opportunities for organised healthcare providers.
Threats
Geographical Revenue Concentration: A significant proportion of consolidated revenue continues to be derived from a single geography, exposing the Company to country-specific economic, regulatory, and political developments until diversification initiatives gain further scale.
Execution Risk in New Facilities: The successful ramp-up of newly commissioned hospitals depends on timely regulatory approvals, doctor onboarding, insurance empanelment, and patient acquisition, any delay in which may impact financial performance.
Competitive Market Environment: The organised hospital sector continues to witness aggressive expansion by established national and regional players, increasing competition for patients, specialists, and strategic locations.
Talent Acquisition and Retention: The ability to attract and retain highly qualified medical professionals and specialists remains critical in an increasingly competitive healthcare landscape.
Regulatory and Political Risks: Operating across multiple jurisdictions exposes the Company to evolving regulatory frameworks, policy changes, licensing requirements, and political developments that could affect operations and expansion timelines.
Foreign Exchange Exposure: International operations expose the Company to currency fluctuations, which may impact reported revenues, profitability, and consolidated financial performance.
Working Capital and Receivable Management:
Extended collection cycles, particularly from institutional and government payers, may increase working capital requirements and impact liquidity available for expansion.
Supply Chain Disruptions: Dependence on imported medical equipment, pharmaceuticals, and consumables exposes operations to potential disruptions arising from global logistics challenges, trade policies, and pricing volatility.
Technology and Cybersecurity Risks: Increasing digitalisation of healthcare delivery elevates the importance of robust cybersecurity, data privacy, and technology infrastructure to safeguard patient information and ensure uninterrupted operations.
Scalability and Cross-Border Execution: Managing expansion across multiple geographies requires effective capital allocation, governance, and operational oversight, while balancing diverse market dynamics and regulatory environments.
RISK MANAGEMENT AND INTERNAL CONTROLS
Operational Risks
Multi-Jurisdictional Regulatory Complexity: Operating across India, Uganda, Tanzania, Nigeria, and the UAE exposes the Company to diverse and evolving regulatory regimes. Licensing requirements, clinical accreditation standards, and healthcare labour regulations differ significantly across these markets, and changes in any jurisdiction can impact operational timelines or compliance costs. The delays experienced in commissioning the Mwanza facility due to Tanzanias election-driven regulatory standstill, illustrate this risk in practice. The Company manages this through dedicated local compliance teams and proactive regulatory engagement.
Execution Risk on New Facility Commissioning: New hospital ramp-ups involve teething challenges, team-building, clinical workflow alignment, corporate empanelment processes, and occupancy build-up, all of which take time. The Companys experience with Navi Mumbai has generated learnings that are now being applied to Nashik, reducing execution risk on each successive facility.
Financial Risks
Currency Volatility: Revenue from Uganda (UGX), Tanzania (TZS), and Nigeria (NGN) is subject to foreign currency translation risk. Depreciation in these currencies against the Indian Rupee can materially affect reported consolidated revenues and profitability. The Company manages this through natural hedging (local currency revenues matching local currency costs) and by increasing the India revenue proportion over time.
Trade Receivables Concentration: Consolidated trade receivables stood at Rs. 123.4 Cr in FY26 versus Rs. 82.2 Cr in FY25, a ~50% increase. The majority of the receivable balance relates to Ugandas government-linked hospital insurance receivables, which carry extended collection cycles of approximately 180200 days (down from 320 days, with a target of 150 days). A further slowdown in Uganda government payments, as experienced in Q4 FY26 due to election-related delays, can have an outsized impact on working capital and liquidity. The Company is addressing this through the India revenue ramp-up (materially lower receivable days), structured government payment schedules, and receivable cycle monitoring. Strategic Risks
Geographic Concentration: Uganda contributed approximately 79% of consolidated revenues in FY26. While this reflects the maturity and scale of the Uganda operations rather than a structural risk per se, it creates vulnerability to country-specific economic, regulatory, or political disruptions. The Companys clear and actively executed strategy of building India revenues to achieve a more balanced mix, with no single non-India geography contributing more than one-third of consolidated revenues, is the primary mitigation.
Talent Retention: The Indian hospital market is intensely competitive for clinical talent, with large corporate chains actively seeking specialist doctors. Unihealths differentiated retention model (flexible scheduling, daily payment settlement, infrastructure parity, and the personal networks of the founder-doctors) has been effective thus far, as evidenced by 130+ consultants on panel at Navi Mumbai. However, sustaining this as the India network scales will require continued investment in the doctor experience.
Government Payment Dependency: A significant portion of Uganda revenues flows through government departments, making the Company partially dependent on government fiscal health and payment timelines. Ugandas recent oil discovery and associated Western investment inflows are expected to improve government healthcare payment capacity over the medium term.
Supply Chain Risks
Import Dependence: A significant proportion of medical consumables, pharmaceuticals, and capital equipment for African operations is imported from India and other markets. This creates exposure to foreign exchange movements, import tariffs, and supply chain disruptions. The Companys pharmaceutical distribution vertical partially mitigates this by providing direct supply chain access, while its diversified sourcing partnerships reduce single-supplier dependency. Internal Controls The Company maintains a comprehensive internal control system commensurate with its size, scale, and operational complexity. The framework integrates documented policies, Standard Operating Procedures, process guidelines, and segregation of duties, supported by increasing automation and digital monitoring.
Internal audits are conducted by an independent firm of Chartered Accountants under a risk-based audit plan, with findings reviewed by Management and presented quarterly to the Audit Committee, which includes independent directors. The accounting software maintains a full audit trail (edit log) as required under Companies Act provisions, and no instances of tampering were identified during the audit. For FY26, Management has evaluated internal controls over financial reporting and found them to be robust and operating effectively. The Statutory Auditors have independently confirmed this assessment.
FUTURE OUTLOOK
Near-Term Focus: FY27
The Company enters FY27 with its most comprehensive and balanced operational platform in its history mature Africa assets generating strong cash flows, and a rapidly scaling India platform poised to add meaningful revenue.
Nashik Commissioning: Patient services are expected to commence by the end of July 2026, with full operational capabilities including MRI, CT, and all specialty OPDs, in place by August 2026. The 200-bed Nashik facility will be the Companys single largest facility by bed count and is expected to contribute meaningfully to FY27 revenues from H2 FY27 onwards. Operational breakeven is targeted within 15-18 months of commissioning.
Navi Mumbai Breakeven: The Navi Mumbai facility is on track to achieve operational breakeven by September 30, 2026 (Q2 FY27), supported by growing occupancy, an ARPOB trajectory ahead of initial projections, and an expanding corporate and insurance empanelment base.
Tanzania Expansion: The Mwanza 20-bed specialised facility is expected to be commissioned imminently upon receipt of the regulatory license. The Dar-es-Salaam 100-bed acquisition is targeted for financial close within 23 months, with immediate revenue contribution upon takeover.
Uganda Receivables: The receivable normalisation programme is expected to accelerate in FY27, with government payments expected in timelines that allows reducing the outstanding receivable days to 180-days.
International Patient Pipeline: With 250+ live inquiries from Africa, and active marketing in Kenya, Nigeria, and prospectively the Middle East, the MVT-to-India referral channel is expected to become a meaningful contributor to Navi Mumbais occupancy and ARPOB in FY27.
FY27 Targets
Commissioned Beds: ~520+ (150 Uganda + 50 Navi Mumbai + 200 Nashik + 120+ Tanzania)
Consolidated Occupancy: ~60%
Consolidated ARPOB: ~ Rs. 27,500+
EBITDA Margin: 3035% (mid-30s as aspirational) Medium-Term Vision: CY2028 The Companys CY2028 vision, consistently articulated since 2023, remains firmly on track: 1,000 commissioned beds across India and Africa, with annualised revenue of approximately Rs. 1.01.1 Cr (based on ~500 occupied beds at Rs. 30,000 consolidated ARPOB). The EBITDA margin profile at this scale, with a mix of ~250300 mature beds, ~200 breaking-even beds, and ~300 recently commissioned beds, is expected to be in the early-to-mid 30s.
Pune Expansion: A 125-bed greenfield facility in Pune is planned as the third leg of the Maharashtra Golden Triangle, targeted for FY2728 commissioning. The PHRC Health City (750 beds), for which Unihealth has been the Project Management Consultant since 2019, represents a Phase 2 Operations & Management opportunity expected to go live around 203132.
International Patient Strategy: Indias medical tourism market, projected to reach US$14.3 billion by 2029, positions Navi Mumbai and Nashik to become significant international patient destinations, drawing from Unihealths deep-rooted Africa and Middle East patient networks. Oman, Iraq, Kenya, and Nigeria are the near-term priority markets for patient activation.
Capital Allocation Priorities: With Uganda now debt-free and India facilities being funded on an asset-light basis, the Companys strong balance sheet (Net Worth Rs. 198 Cr, D/E 0.11x) provides ample headroom to fund its growth roadmap. Where debt is required for equipment or facility financing, the Company will do so judiciously, maintaining leverage well within conservative thresholds.
Cautionary Statement
Certain statements contained in this Management Discussion and Analysis are forward-looking in nature and are based on the Companys current expectations, estimates, and assumptions. These statements are subject to various risks and uncertainties, including changes in economic conditions, government policies, regulatory frameworks, technological developments, currency fluctuations, competitive dynamics, and other factors that may cause actual results to differ materially from those anticipated. Accordingly, readers are advised not to place undue reliance on such statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements in light of new information, future events, or otherwise. This Management Discussion and Analysis has been prepared by the Management of Unihealth Hospitals Limited for the financial year ended March 31, 2026.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.